Related Experiment Video
Updated: Jul 10, 2026
Vascular Reconstruction with the Cuff Technique in Mouse Orthotopic Liver Transplantation
Published on: December 1, 2023
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series
Yasuhiko Sugawara1, Sumihito Tamura, Masatoshi Makuuchi
1Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. yasusuga-tky@umin.ac.jp
Background/Aims:
Hepatocellular carcinoma (HCC) is one of the major indications for living donor liver transplantation (LDLT). Unlike in deceased donor liver transplantation, however, there exist no universally adopted selection criteria for the potential candidates with HCC in LDLT. Our institutional guideline for HCC in LDLT has been up to 5 nodules with a maximum diameter of 5 cm (5-5 rule).
Methods:
A total of 78 adult patients underwent adult living donor liver transplantation at University of Tokyo between April 1996 and October 2005.
Results:
Overall and recurrence-free survival at 5 years after transplantation were 75 and 90%, respectively, with a median follow-up of 2 years. When stratified by the 5-5 rule, recurrence-free survival at 3 years for patients fulfilling the criteria and those exceeding the criteria was 94 and 50%, respectively.
Conclusions:
In LDLT, the indication for HCC might be expanded from the Milan criteria, with equivalent outcomes. Further study, however, is necessary to justify the general application of the 5-5 rule.
